News coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9664453456993 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Bellerophon Therapeutics in a report on Friday, May 11th. ValuEngine raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 8th. Finally, Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 6th.

Shares of Bellerophon Therapeutics traded down $0.03, hitting $0.63, on Friday, MarketBeat Ratings reports. 754,428 shares of the company’s stock traded hands, compared to its average volume of 1,045,595. Bellerophon Therapeutics has a one year low of $0.47 and a one year high of $3.30. The firm has a market cap of $38.15 million, a P/E ratio of -0.70 and a beta of -0.39.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter. equities analysts predict that Bellerophon Therapeutics will post -0.4 earnings per share for the current fiscal year.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.